Table 3. Analysis Restricted to the Total Tumors Reported in the 1376 Affected Male BRCA1/2 Pathogenic Variant (PV) Carriers Within CIMBA Data Set and Odds Ratios (ORs) in Predicting BRCA2 PV Carrier Status.
| Cancer diagnosis | No. (%) | Adjusted OR (95% CI)a | P value | ||
|---|---|---|---|---|---|
| Total | BRCA1 | BRCA2 | |||
| All cancers | 1634 | 494 | 1140 | 1.00 [Reference] | |
| Male breast cancer | 577 (35.3) | 63 (12.7) | 514 (45.1) | 5.47 (4.06-7.37) | <.001 |
| Prostate cancer | 414 (25.3) | 112 (22.7) | 302 (26.5) | 1.39 (1.09-1.78) | .008 |
| Cancers other than breast and prostate | 643 (39.4) | 319 (64.6) | 324 (28.4) | 0.22 (0.18-0.28) | <.001 |
| Colorectal cancer | 84 (13.1) | 55 (17.2) | 29 (9.0) | 0.47 (0.29-0.78) | .003 |
| Melanoma | 62 (9.6) | 33 (10.3) | 29 (9.0) | 0.76 (0.43-1.34) | .35 |
| Pancreatic cancer | 48 (7.5) | 13 (4.1) | 35 (10.8) | 3.00 (1.55-5.81) | .001 |
Abbreviation: CIMBA, Consortium of Investigators of Modifiers of BRCA1/2.
a
Analyses adjusted for age at cancer diagnosis/last follow-up, country of origin and calendar year of interview.